Consensus Johnson & Johnson

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX 01:46:32 2024-04-23 pm EDT 5-day change 1st Jan Change
150.3 USD +0.82% Intraday chart for Johnson & Johnson +3.95% -4.20%

Evolution of the average Target Price on Johnson & Johnson

Price target over the last 5 years

History of analyst recommendation changes

b49122fae0b3382d298da7ecd11388.PbB09NWdIgMeF1UkpMd0Eoialm2fEyS1cr_W0XIHIGM.d-Mkg5_5TDZZZgIS67U9YL_L5R_uWBfqAu-hmCJrEQZn7zy74c10a1BAZQ~090a4526f70aa8871af053e056833d4a
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169 MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160 MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating MT
The market awaits the BCE meeting and earnings reports Our Logo
The start of a new bull market? Our Logo
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26 MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating MT
ANALYST RECOMMENDATIONS : Adobe, Airbnb, Netflix, Nike, Etsy... Our Logo
Wells Fargo Downgrades Johnson & Johnson to Equalweight From Overweight, Cuts Price Target to $163 From $170 MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $170 From $171, Keeps Equalweight Rating MT
Job losses delight investors Our Logo
RBC Raises Price Target on Johnson & Johnson to $181 From $178, 'Encouraged' by Enterprise Business Review, Keeps Outperform Rating MT
UBS Upgrades Johnson & Johnson to Buy From Neutral, Raises Price Target to $180 From $167 MT
J&J : Wells Fargo remains positive, lowers target CF
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.1 USD
Average target price
173.6 USD
Spread / Average Target
+16.41%
High Price Target
215 USD
Spread / Highest target
+44.18%
Low Price Target
155 USD
Spread / Lowest Target
+3.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Johnson & Johnson

Daiwa Securities
HSBC
DZ Bank
Bernstein
BofA Securities
Morgan Stanley
RBC Capital Markets
Raymond James
Stifel Nicolaus
Guggenheim
Wells Fargo Securities
UBS
Atlantic Equities
Barclays
JPMorgan Chase
Credit Suisse
SVB Securities LLC
Citigroup
Goldman Sachs
DA Davidson
SVB Financial
Sanford Bernstein
Cantor Fitzgerald
J.P. Morgan Chase
Cowen
SVB Leerink
RBC Brandon Henry
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. Consensus Johnson & Johnson